Magazine Article | January 4, 2022

Cell & Gene Therapy Outsourcing Process Development

Source: Life Science Leader

By Industry Standard Research

Half of respondents who outsource cell and/or gene manufacturing activities to CDMOs are outsourcing process development to ensure the ability to scale up manufacturing should the therapy advance toward commercialization. Respondents from large biopharma companies are slightly more likely to outsource this activity in the near future when compared to respondents from nonlarge biopharma companies (52% vs 45%).

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: